YD Bio Limited
YD Bio Limited (YDES): 16 pipeline candidates · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
3.2 months
D/E -5.83 · 0% dilution
N/A
16 candidates
N/A
N/A
A transparent, data-derived signal for YD Bio Limitedacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$231.6M
Cash
$6.0M
Quarterly Burn
$6.6M
Runway
3.2 mo
Revenue
$597K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (16 candidates)
Showing 10 of 16 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$889K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 60,236 | $464K |
| cypress capital management llc (wy) | 30,690 | $236K |
| citadel advisors llc | 19,450 | $150K |
| wolverine asset management llc | 4,886 | $38K |
| morgan stanley | 223 | $2K |
| fmr llc | 1 | $8 |
Frequently asked questions
How many drug candidates are in YD Bio Limited's pipeline?
YD Bio Limited (YDES) has 16 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is YD Bio Limited's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, YD Bio Limited has approximately 3.2 months of cash runway.
What is YD Bio Limited's market capitalization?
YD Bio Limited's market capitalization is approximately $231.6M.
Who is the CEO of YD Bio Limited?
Dr. Ethan Shen Ph.D. is the chief executive officer of YD Bio Limited (YDES).
Get the full picture on YD Bio Limited
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.